DNA gene fusion vaccines against cancer

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 1, 2002, Pages 41-48

  Zhu, Delin ^a   Stevenson, Freda K ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cognate T cell help; DC targeting; DNA fusion vaccines; Genetic immunization; Heat shock proteins; Manipulation of immune pathways; Tumor immunotherapy

Indexed keywords

ANTIGEN; CANCER VACCINE; CD4 ANTIGEN; DNA VACCINE; PLASMID DNA;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERANCE; FUSION GENE; GENE CONSTRUCT; GENETIC MANIPULATION; HELPER CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; NONHUMAN; VACCINATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; COMPLEMENT C3D; CYTOKINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; VACCINES, DNA;

EID: 0036086001     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. DNA vaccines: Immunology, application and optimization
2. DNA vaccines for viral infections: Basic studies and applications
3. DNA vaccination against cancer antigens
4. DNA-based immunotherapeutics for the treatment of allergic disease
5. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
6. Induction of antigen-specific cytotoxic T-lymphocytes in humans by a malaria DNA vaccine
7. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of β-chemokines
8. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers
9. Induction of antigen-specific CD8+ T-cells, T-helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine
10. The role of CpG motifs in innate immunity
11. A Toll-like receptor recognizes bacterial DNA
12. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition
13. Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells
14. DNA-based immunization by in vivo transfection of dendritic cells
15. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
16. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T-cells after gene gun immunization
17. Gene vaccination with naked plasmid DNA: Mechanism of CTL priming
18. Priming of cytotoxic T-lymphocytes by DNA vaccines: Requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes
19. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites
20. In vivo priming by DNA injection occurs predominantly by antigen transfer
21. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope
22. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery
23. Different T-helper cell types and antibody isotypes generated by saline and gene gun DNA immunization
24. Innate immunity
25. Genetic adjuvants for DNA vaccines
26. A nine-amino acid peptide from IL-1β augments antitumor immune responses induced by protein and DNA vaccines
27. Insertion of the DNA for the 163-171 peptide of IL1β enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice
28. The complement system and adaptive immunity
29. Natural antibodies and complement link innate and acquired immunity
30. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity
31. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge
32. Enhanced avidity maturation of antibody to Human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins
33. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex
34. Cross-presentation, dendritic cells, tolerance and immunity
35. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction
36. A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge
37. Site-directed immune responses in DNA vaccines encoding ligand-antigen fusions
38. Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudotuberculosis in sheep
39. Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen
40. Targeting dendritic cells to enhance DNA vaccine potency
41. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor-α
42. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization
43. B-cell malignancies as a model for cancer vaccines: From prototype protein to next generation genetic chemokine fusions
44. The biology of chemokines and their receptors
45. Lymphocyte traffic control by chemokines
46. HIV-1 DNA vaccines and chemokines
47. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity
48. Immunobiology of dendritic cells
49. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T-lymphocytes
50. DNA vaccination against tuberculosis: Expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity
51. DNA immunization: Ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction
52. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine
53. DNA immunization with minigenes: Low frequency of memory cytotoxic T-lymphocytes and inefficient antiviral protection are rectified by ubiquitination
54. Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens
55. Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination
56. Heat shock proteins: The fountainhead of innate and adaptive immune responses
57. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin
58. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene
59. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen
60. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments
61. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen
62. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth
63. Danger signals: SOS to the immune system
64. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway
65. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor
66. HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine
67. Human 60-kDa heat-shock protein: A danger signal to the innate immune system
68. Cutting edge: Heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells
69. Get into the groovel Targeting antigens to MHC class II
70. Hijacking a chaperone: Manipulation of the MHC class II presentation pathway
71. MHC class II-restricted antigen processing and presentation
72. Induction of antigen specific CD4+ T-cell responses by invariant chain based DNA vaccines
73. Efficient loading of HLA-DR with a T-helper epitope by genetic exchange of CLIP
74. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells
75. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T-helper epitope by genetic exchange of the class II-associated invariant chain peptide
76. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens
77. Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T-cells
78. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors
79. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells
80. The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T-cell immunity
81. The role of CD4+ T-cell responses in antitumor immunity
82. CD4 T-cells and their role in antitumor immune responses
83. DNA immunization induces protective immunity against B-cell lymphoma
84. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma
85. DNA vaccines against lymphoma: Promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C
86. Overcoming the poor immunogenicity of a protein by DNA immunization as a fusion construct
87. Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies
88. Functional cooperation between T helper cell determinants
89. In vivo induction of specific cytotoxic T-lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen
90. Anti-tumor immunity against CT26 colon tumor in mice immunized with plasmid DNA encoding β-galactosidase fused to an envelope protein of endogenous retrovirus
91. DNA fusion vaccines designed to induce cytotoxic T-cell responses against defined peptide motifs: Implications for cancer vaccines
92. Advances in plasmid gene delivery and expression in skeletal muscle
93. The prime-boost strategy: Exciting prospects for improved vaccination